Trump has warned of pharmaceutical companies about ‘fare wall’ and can increase the price of pharmaceuticals – Trump warns the pharmaceutical companies of the Trump.
US President Donald Trump has warned that pharmaceutical companies are planning to install a fee wall for pharmaceutical companies. Under this, 25% of the tariffs for importing drugs in the US market can increase by up to 12.9% of the US drug. Because of this, the price of drugs in the US market may increase by about $ 51 billion per year.
According to Reuters, a report has been published, which has been appointed by the US Business Committee. In 2023, the United States has reportedly imported $ 203 billion pharmaceutical products, with 73% of which came from Europe, especially from Ireland, Germany and Switzerland. In the same year, the total drug sales of the United States were $ 393 billion.
This step by this Trump may further increase the fear that the price of US drugs will increase, which will cause additional economic pressure on patients and health services.
According to Reuters, the US can impose a 25% fee for pharmaceutical products, which can increase the price of US pharmaceuticals by approximately $ 51 billion annually. If this fee is used, the prices of the drug may increase by 12.9%.
The report was appointed by Pharmaceutical Research and Manufacturers (BRMA) in the United States, which includes companies such as Bristol Mers Squib, Eli Lily and Faizer. The BRMA states that Trump’s main goal will weaken this fee with efforts to increase domestic production. The Trump administration’s pharmaceutical companies have urged the Trump administration to gradually implement fees on imported pharmaceutical products, which can reduce its economic success.
The report states that the cost of new drugs is not the cost of production. However, it is not clear how much of imported intermediate products or imported finished product fees will affect the consumers.
If the charges are used in the finished product, it can be achieved by retail and total distributors. According to the report, if the high cost fees in domestic sales are fully implemented, the prices of US drugs may increase by 12.9%.
